WHO更新治疗指南：对伊维菌素，羟氯喹等COVID-19 抗病毒药物

[metropolis]

伊维菌素
WHO 指南指出不建议在临床环境中用于 COVID-19 患者。

WHO 表示，强烈建议任何 COVID-19 患者不要使用羟氯喹、洛匹那韦-利托那韦、卡西里单抗和依德维单抗等药物。​

Ivermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO's updated treatment guidelines​

https://bbs.comefromchina.com/javascript:;
Alexandra Mae Jones
CTVNews.ca writer
Follow | Contact
Published Nov. 10, 2023 5:21 a.m. EST

In this Sept. 10, 2021, file photo, a syringe of ivermectin, a drug used to kill worms and other parasites, rests on the box it was packaged in, in Olympia, Wash. (AP Photo/Ted S. Warren, File)​

UPDATED WARNINGS FOR USE OF IVERMECTIN AND A NEW ANTIVIRAL​

VV116​

When COVID-19 emerged in late 2019 and quickly spread across the globe in 2020, researchers immediately began to investigate which existing drugs could be repurposed to treat the virus. But researchers in China also began to develop a therapeutic aimed specifically at tackling COVID-19, which they presented preliminary research for in 2021.

Because VV116 was created to tackle COVID-19 specifically, research assessing its effectiveness is still new.

It is an oral antiviral drug which induces RNA chain termination to interfere with the spread of the virus. While WHO notes that it “does not seem to be associated with increased adverse effects,” there still isn’t enough data to recommend it at this stage, according to the agency.

Only one randomised control trial has formally assessed its effectiveness by comparing it with Paxlovid. Although the trial found that VV116 was noninferior compared to Paxlovid, no deaths were recorded in the entire trial, making it difficult to assess if the medication itself had any impact in preventing mortality, WHO stated. There was also no placebo control group in the trial.

The updated guidelines reflect that WHO strongly recommends against VV116 being used for COVID-19 patients regardless of how serious their illness is, except in the context of a clinical trial.

Ivermectin​

Despite widespread use of ivermectin, a medication approved for use in humans to treat parasitic infections such as river blindness, it is still not recommended for use with COVID-19 patients in clinical settings, the WHO guidelines state.

But WHO is now also strongly warning against its use for those with non-severe COVID-19, even in research settings.

New research that has emerged since 2021 has reduced the uncertainty surrounding whether or not it is worth continuing randomised controlled trials assessing ivermectin’s usage for those with non-severe COVID-19, WHO states.

This data shows a “very low likelihood of benefit,” both due to research that has tested and also due to the “lack of biological basis for any effect of ivermectin on the virus.” Essentially, it was always scientifically unlikely that it would have an effect, and it hasn’t been shown to have one.

Ivermectin is conditionally recommended against in research settings for severe cases of COVID-19 as well.

“Use of ivermectin risks diverting attention and resources away from care likely to provide a benefit such as nirmatrelvir/ritonavir, remdesivir, and molnupiravir as well as supportive care interventions,” WHO states, adding that it risks causing drug shortages for those suffering from issues ivermectin is actually designed to tackle.

Drugs such as hydroxychloroquine, lopinavir-ritonavir, casirivimab and imdevimab are strongly recommended to not be used with any COVID-19 patients, according to WHO.

RELATED IMAGES

In this Thursday Oct. 15, 2020 file photo, a bottle containing the drug Remdesivir is held by a health worker at the Institute of Infectology of Kenezy Gyula Teaching Hospital of the University of Debrecen in Debrecen, Hungary. (Zsolt Czegledi/MTI via AP, File)

Ivermectin warnings, a new COVID-19 antiviral, a changing threshold for care: These are the WHO's updated treatment guidelines

The World Health Organization has updated its guidelines for the treatment of COVID-19 patients, including categories of hospitalization risk to help doctors tailor treatment, and recommendations surrounding a new antiviral designed specifically to tackle the disease.

www.ctvnews.ca

 

[贵圈]

使劲打疫苗。北美现在都不敢统计了，就怕没人打，丢脸。

 

[贵圈]

covid必须信政委。马啊。

 

[贵圈]

11月份更新

 

[贵圈]

什么是

Acetaminophen？​

这东西既然吃了以后，病情更重？risk提高明显。虽然covid这两年，大家都被医生推荐使用的感冒药。经过临床观察，才知道，是毒药。

Acetaminophen is often known as Tylenol or other brand names. It is classified as a pain reliever (analgesic) and fever reducer (antipyretic). Ibuprofen is often known by its given name, but you may also know it as Advil or Motrin. It is classified as a nonsteroidal anti-inflammatory drug (NSAID)

这就是去年开始狂推的泰勒啊。

 

[贵圈]

Iburpofen, advil，也不咋地。

 

[贵圈]

pax神药吧，药厂和市委书记都狂推。市场也跌惨了。

不仅仅是病毒复发（病毒会快速进化），而且效果不咋地。而且是基因复制干扰药物。这么猛的药，综合结果还不如
HCQ和锌。

这神药还不许独立研究做验证实验。牛逼坏了。

 

[贵圈]

还是IVM真正有效，这是研究集成。不是个别文章。大幅降低风险。

Statistically significant lower risk is seen for mortality, ventilation, ICU admission, hospitalization, recovery, cases, and viral clearance. All remain significant for higher quality studies. 60 studies from 54 independent teams in 24 different countries show statistically significant improvements.
•Meta analysis using the most serious outcome shows 62% [51‑70%] and 85% [77‑90%] lower risk for early treatment and prophylaxis, with similar results for higher quality studies, primary outcomes, peer-reviewed studies, and for RCTs.

•Results are very robust — in worst case exclusion sensitivity analysis 62 of 99 studies must be excluded to avoid finding statistically significant efficacy.
•No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, which may be significantly more effective. Pharmacokinetics show significant inter-individual variability Guzzo. Efficacy may vary depending on the manufacturer Williams.
•Over 20 countries adopted ivermectin for COVID-19. The evidence base is much larger and has much lower conflict of interest than typically used to approve drugs.
•All data to reproduce this paper and sources are in the appendix. Multiple other meta analyses show efficacy Bryant, Hariyanto, Kory, Lawrie, Nardelli.


•从统计学上看，死亡率、通气、入住 ICU、住院、康复、病例和病毒清除的风险显着降低。所有这些对于更高质量的研究仍然具有重要意义。来自 24 个不同国家的 54 个独立团队的 60 项研究显示出统计上显着的改善。
•使用最严重结局的荟萃分析显示， 早期治疗和预防的风险降低了62% [51-70%]和 85% [77-90%]，更高 质量的研究、 主要结局、同行评审研究和用于 随机对照试验。
•结果非常稳健——在最坏的情况下，排除敏感性分析必须排除 99 项研究中的 62 项，以避免发现统计学上显着的疗效。
•没有任何治疗或干预是 100% 有效的。所有实用、有效、安全的手段都应基于风险/收益分析来使用。 多种治疗通常结合使用，这可能会更有效。药代动力学显示出显着的个体差异Guzzo。功效可能因威廉姆斯制造商而异。
•20 多个国家/地区采用伊维菌素治疗 COVID-19。与通常用于批准药物的证据基础相比，证据基础要大得多，利益冲突也少得多。
•复制本文的所有数据和来源都在附录中。多项其他荟萃分析显示了 Bryant、Hariyanto、Kory、Lawrie、Nardelli的功效。

 

[贵圈]

新冠又起，居然还有人买拐。真的是。。。追责当初禁用IVM的责任是，各方都开始推诿了。还有人信。。。。

药厂都股价崩了。

 

[贵圈]

辉瑞，生产两个东西，疫苗和pax神药。

全完。

 

[metropolis]

新冠又起，居然还有人买拐。真的是。。。追责当初禁用IVM的责任是，各方都开始推诿了。还有人信。。。。

药厂都股价崩了。

浏览附件1117948

没看出这两张图的区别。

WHO 的最新指南主要是针对COVID治疗药物和疫苗没有直接关系。

果然是一石激起千层浪，你我都尽力了。兼听则明，偏信则暗，这里都是明白人，自行选择。

 

[So what]

别的咱不懂，那个伊维菌素听着耳熟啊？不就是某专家竭力推荐的那种马药，对的，给马驱虫的，竟然WHO至今还不接受嘛

 

[贵圈]

没看出这两张图的区别。

WHO 的最新指南主要是针对COVID治疗药物和疫苗没有直接关系。

果然是一石激起千层浪，你我都尽力了。兼听则明，偏信则暗，这里都是明白人，自行选择。

我则是不仅仅针对疫苗，也针对神药。哈哈哈。可惜了，现在说事儿，连数据都不给了，当年林大米健在的时候，跟我吵IVM，好歹还引经据典的。

可惜了，走了。

 

[贵圈]

别的咱不懂，那个伊维菌素听着耳熟啊？不就是某专家竭力推荐的那种马药，对的，给马驱虫的，竟然WHO至今还不接受嘛

马。的确是不懂。哈哈。

 

[贵圈]

盼着林大米回来，至少有点料。不那么干巴巴的。